Tuesday, June 14th, 2016 - Newscaster Press Release

Australia - St. Vincent's Hospital, Melbourne, Victoria | Royal Melbourne Hospital, Parkville, Victoria | Linear Clinical Research Ltd, Nedlands, Western Australia | Royal Prince Alfred Hospital, New South Wales  -  Hepatitis B is a virus that is spread through contact with the blood or bodily fluids of an infected person.

In Australia, approximately 225,000 people are living with chronic Hepatitis B, which is defined as having had the infection for longer than six months.

However, according to Hepatitis Australia, nearly half of those living with chronic Hepatitis B in Australia are undiagnosed.

A clinical trial is now open for people who have been diagnosed with chronic Hepatitis B Virus (HBV) infection, who have not had treatment for this condition in the last 2 years. Other entry requirements apply.

This clinical trial has been reviewed and approved in accordance with the Australian Human Research Ethics Committee process.

The purpose of this research study is to assess the effectiveness and safety of a novel medicine for the treatment of patients with chronic Hepatitis B.

Participating clinics include leading hospitals and medical centres. 

The study will assess the effects of the study medicine alone or in combination with other Hepatitis B treatments such as entecavir and pegylated interferon alpha 2a therapy.

Patients will need to agree to participate in the study for approximately 96 weeks, involving 31 clinic visits and a preliminary screening period of up to 60 days.

Travel expenses to clinic appointments will be reimbursed upon presentation of receipts or appropriate documentation.

Patients will need to provide written informed consent to enter into the study.

Clinic staff will discuss any other factors that may determine eligibility. 

If you think you might be eligible, please click here to find your nearest participating clinic.  http://bit.ly/HepB-Clinical-TrialAUNZ

Contact them for more information and book a medical screening appointment. 

The study can enroll up to 96 people. All study medication, medical appointments, and tests are free of charge.

 

 

Press Release Heparc-2008 | 28-April-2016 Version 2 AU

Contact Profile

Newscaster Press Release


Newscaster by TrialWire is the advanced press release news service connecting potential patients with relevant clinical trials.


Newscaster Media Team
P: AU +61 2 8218 2144
M: USA +1 650 798 5238
W: www.trial-wire.com/

Keywords

Hepatitis B, Hepatitis Australia, HBV, chronic Hepatitis B, liver disease, Hepatitis B Virus, entecavir, pegylated interferon alpha 2a therapy, Heparc-2008, gastroenterologist, HBsAg, hepatitis B surface antigen, HBsAb, Anti-HBs

Categories

Sharing

More Formats